Only 3% were classified as variants of strong clinical significance in BRCA1 and BRCA2 of ovarian high-grade serous (HGSC) and uterine endometrioid carcinoma. This evidence concerns the gene BRCA2 and endometrial endometrioid adenocarcinoma.